Items where Author is "Micaleff, Alain"

Article

Hughes, David, Waddingham, E., Mt-Isa, S., Goginsky, Alesia, Chan, Edmond, Downey, Gerald, Hallgreen, C. E., Hockley, K.S., Juhaeri, J., Lieftucht, Alfons, Metcalf, M.A., Noel, R.A., Phillips, L.D., Ashby, Deborah and Micaleff, Alain (2016) Recommendations for benefit–risk assessment methodologies and visual representations. Pharmacoepidemiology and Drug Safety, 25 (3). pp. 251-262. ISSN 1053-8569

Hughes, David, Talbot, S., Mt-Isa, S., Lieftucht, Alfons, Phillips, L.D., Asiimwe, Alex, Hallgreen, C. E., Downey, G., Genov, G., Hermann, Richard, Metcalf, M.A., Noel, R.A., Tzoulaki, I., Ashby, Deborah and Micaleff, Alain (2015) Literature review of visual representation of the results of benefit–risk assessments of medicinal products. Pharmacoepidemiology and Drug Safety, 25 (3). pp. 238-250. ISSN 1053-8569

Mt-Isa, Shahrul, Hallgreen, Christine E., Wang, Nan, Callréus, Torbjörn, Genov, Georgy, Hirsch, Ian, Hobbiger, Stephen F., Hockley, Kimberley S., Luciani, Davide, Phillips, Lawrence D., Quartey, George, Sarac, Sinan B., Stoeckert, Isabelle, Tzoulaki, Ioanna, Micaleff, Alain and Ashby, Deborah (2014) Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiology and Drug Safety, 23 (7). pp. 667-678. ISSN 1053-8569

Monograph

Hughes, Diana, Waddingham, Ed, A., J., Mt-Isa, Shahrul, Goginsky, Alesia, Chan, Edmond, Downey, Gerald, Hallgreen, Christine E., Hockley, Kimberley S., Juhaeri, Juhaeri, Lieftucht, Alfons, Metcalfe, Marilyn, A., Noel, Rebecca, A., Phillips, Lawrence D., Ashby, Deborah and Micaleff, Alain (2014) IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines. . PROTECT Consortium, London.

Micaleff, Alain, Callreus, Tornbjorn, Phillips, Lawrence D., Hughes, Diana, Hockley, Kimberley, Wang, Nan and Luciani, David (2013) IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab). . PROTECT Consortium, London.

Phillips, Lawrence D., Amzal, Billy, Asiimwe, Alex, Chan, Edmond, Chen, Chen, Hughes, Diana, Juhaeri, Juhaeri, Micaleff, Alain, Mt-Isa, Shahrul, Noel, Becky, Shepherd, Susan and Wang, Nan (2013) IMI work package 5: report 2:b:ii benefit - riskwave 2 case study report: Rosiglitazone. . PROTECT Consortium, London.

Mt-Isa, Shahrul, Hallgreen, Christine, E., Asiimwe, Alex, Downey, Gerry, Genov, Georgy, Hermann, Richard, Hughes, Diana, Lieftucht, Alfons, Noel, Rebecca, Peters, Ruth, Phillips, Lawrence D., Shepherd, Susan, Micaleff, Alain, Ashby, Deborah and Tzoulak, Ioanna (2013) Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: stage 2 of 2. . PROTECT Consortium, London.